KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Accumulated Expenses: 2017-2024

Historic Other Accumulated Expenses for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $221.0 million.

  • Moderna's Other Accumulated Expenses rose 5.80% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.0 million, marking a year-over-year increase of 5.80%. This contributed to the annual value of $221.0 million for FY2024, which is 71.32% up from last year.
  • According to the latest figures from FY2024, Moderna's Other Accumulated Expenses is $221.0 million, which was up 71.32% from $129.0 million recorded in FY2023.
  • In the past 5 years, Moderna's Other Accumulated Expenses ranged from a high of $249.0 million in FY2022 and a low of $34.0 million during FY2020.
  • For the 3-year period, Moderna's Other Accumulated Expenses averaged around $199.7 million, with its median value being $221.0 million (2024).
  • As far as peak fluctuations go, Moderna's Other Accumulated Expenses surged by 571.54% in 2020, and later crashed by 48.19% in 2023.
  • Over the past 5 years, Moderna's Other Accumulated Expenses (Yearly) stood at $34.0 million in 2020, then skyrocketed by 561.76% to $225.0 million in 2021, then climbed by 10.67% to $249.0 million in 2022, then crashed by 48.19% to $129.0 million in 2023, then soared by 71.32% to $221.0 million in 2024.